Cimzia® and Epratuzumab presented by UCB at EULAR 2008

Dear All,

Please find attached, for your information, the press releases which were published at the occasion of the 2008 EULAR (European League Against Rheumatism) congress in Paris.

- CIMZIA® IS THE FIRST ANTI-TNF SHOWN TO INHIBIT PROGRESSION OF JOINT DAMAGE AS EARLY AS 16 WEEKS IN RHEUMATOID ARTHRITIS

- EPRATUZUMAB REDUCED DISEASE ACTIVITY AND STEROID USE IN PATIENTS WITH MODERATE AND SEVERE FLARING SLE

Best regards,

UCB Investor Relations Team